Mobile Health Technology for Chronic Kidney Disease Patients: Medication Management
NCT ID: NCT02905474
Last Updated: 2017-11-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
182 participants
INTERVENTIONAL
2016-05-31
2017-09-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Design: We propose to conduct an open-label randomized controlled trial to assess the medication related effectiveness and stakeholders' satisfaction of the eKidneyCare mobile app compared to commercially available mobile apps like My MedRec for 12 months. This study will be conducted in the renal clinics at University Health Network who oversee the clinical management of advanced stage 4 to 5 CKD patients and end stage renal disease. On average, patients of this clinic are aged 65 years or more and take 10-15 medications per day.
Objectives and Hypotheses Primary 1) To evaluate the effect of the eKidneyCare mobile app compared to a commercially available stand alone mobile app (My MedRec) on unintentional medication discrepancies in CKD patients. The use of the eKidneyCare app will have a greater reduction medication discrepancy rates by enhancing patient self-care through bidirectional communication of information.
Secondary
1. To determine the effect of the eKidneyCare mobile app compared to commercially available stand along mobile app (My MedRec) on CKD-specific clinical outcomes. Patients actively engaged in medication management will translate to improved clinical parameters such as better blood pressure control.
2. To evaluate the direct costs and quality of life (QOL) associated with incorporating the eKidneyCare mobile app compared to commercially available stand along mobile app (My MedRec). Reduction in the unintentional medication discrepancy rate will offset the cost of using the medication self-care app and will improve patients' quality of life.
3. To assess stakeholders' satisfaction in using the mobile app to manage CKD. Medication self-care app will increase satisfaction among patients.
This study will evaluated if this app will decrease errors related to medications. It is hypothesized that if patients use this app to report their medications to their doctors, fewer errors will occur, which should eventually lead to reduced patient harm and healthcare use.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
eKidneyCare
The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.
Usual Care
Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
Integrated mobile medication app
Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
My MedRec (Commercial App)
My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.
Usual Care
Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
Commercially available mobile medication app
Use of mobile app to manually record and maintain medication records with no integration to databases.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Usual Care
Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
Integrated mobile medication app
Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
Commercially available mobile medication app
Use of mobile app to manually record and maintain medication records with no integration to databases.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* English-speaking
* Able and willing to provide informed consent
Exclusion Criteria
* likely to receive a kidney transplant within 3 months of enrollment into the trial
* living in a long-term care or rehabilitation institution, likely to have their care transferred to another facility outside participating clinic areas during the course of the study
* taking less than 2 prescription medications
* planning to travel or live consecutively out of the province of Ontario for more than one month
* participating in another intervention trial,
* cognitive impairment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephanie W Ong, BScPHM, MSc
Role: PRINCIPAL_INVESTIGATOR
UHN
Alexander G Logan, MD, FRCP(C)
Role: PRINCIPAL_INVESTIGATOR
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Health Network
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ong SW, Jassal SV, Porter EC, Min KK, Uddin A, Cafazzo JA, Rac VE, Tomlinson G, Logan AG. Digital Applications Targeting Medication Safety in Ambulatory High-Risk CKD Patients: Randomized Controlled Clinical Trial. Clin J Am Soc Nephrol. 2021 Apr 7;16(4):532-542. doi: 10.2215/CJN.15020920. Epub 2021 Mar 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHN-16-5002-BE
Identifier Type: -
Identifier Source: org_study_id